Who are Trivastal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alphagan, Alphagan, Ritalin, Concerta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/piribedil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Trivastal — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trivastal (PIRIBEDIL) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: piribedil. Area: Neuroscience.

phase 3 piribedil Alpha-2C adrenergic receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Trivastal (PIRIBEDIL). Trivastal works by blocking the alpha-2C adrenergic receptor, which helps to increase dopamine levels in the brain.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trivastal TARGET	PIRIBEDIL		phase 3	piribedil	Alpha-2C adrenergic receptor
Alphagan	BRIMONIDINE TARTRATE	Senju Pharmaceutical Co., Ltd	marketed	alpha-Adrenergic Agonist	Alpha-2C adrenergic receptor	1996-01-01
Alphagan	BRIMONIDINE	Senju Pharmaceutical Co., Ltd	marketed	alpha-Adrenergic Agonist	Alpha-2C adrenergic receptor	1996-01-01
Ritalin	methylphenidate	Novartis	marketed		Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor
Concerta	Concerta	Lei Lei, MD	marketed		Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor

Recent regulatory actions (last 90 days)

2026-05-07 — Alphagan · FDA · approved · US · Senju Pharmaceutical Co., Ltd
2026-04-16 — Alphagan · FDA · approved · US · Senju Pharmaceutical Co., Ltd

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-06-28 — Ritalin · 9072680 · Formulation · US
2032-06-28 — Ritalin · 9089496 · Formulation · US
2038-01-25 — Ritalin · 11166947 · Method of Use · US

Sponsor landscape (piribedil class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trivastal — Competitive Intelligence Brief. https://druglandscape.com/ci/piribedil. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing